Biocross announces AAIC 2016 poster

Biocross announces AAIC 2016 poster

Biocross is pleased to present at the 2016 Alzheimer’s Association International Conference (AAIC) in Toronto its work on the influence of APOE ε4 carrier status on the metabolomic profile of AD patients versus cognitively normal controls. The AAIC is the...
Matthew Mittino, new CEO of Biocross

Matthew Mittino, new CEO of Biocross

Biocross has appointed Matthew Mittino as its new CEO. Biocross is currently developing several projects centered on the diagnosis of Alzheimer’s disease and the identification of populations at risk of developing the disease. Over the last 20 years Matthew’s...
Will Spain put an end to Alzheimer’s?

Will Spain put an end to Alzheimer’s?

Early diagnosis of this disease is one of the factors that would enable better treatment. This is a key focus of many of the biotechnology companies that have emerged in recent decades. In Spain and in other countries, several research projects are currently underway,...